On June 29, 2022, MiroBio, a leader in the development of checkpoint agonists to treat autoimmune diseases, announced the completion of a $97million (£80 million) Series B financing led by Medicxi with participation from new investors, OrbiMed and Monograph Capital, and existing Series A investors, Oxford Science Enterprises, Samsara BioCapital, SR One, and Advent Life Sciences. Wilson Sonsini Goodrich & Rosati advised MiroBio on the transaction.

Funds from the Series B will primarily be used to advance MiroBio’s two lead antibody candidates into clinical trials and obtain safety and efficacy data in patients with autoimmune diseases. MB272 and MB151 are differentiated, precision-engineered checkpoint receptor agonists for BTLA (B- and T-Lymphocyte Attenuator) and PD-1 (Programmed cell Death protein 1) respectively, offering transformative therapeutic potential for patients. Proceeds will also be used to advance MiroBio’s pre-clinical pipeline and further develop the company’s proprietary I-ReSToRE discovery platform. Following the fundraising Nick Williams of Medicxi and Erez Chimovits of OrbiMed will join MiroBio’s Board of Directors.

The Wilson Sonsini team that advised MiroBio on the transaction includes Louis Lieto, Tom Owens, and Wei Huang.

For more information, please see MiroBio’s press release.